Total Payments
$5,137
2024 Payments
$490.47
Companies
28
Transactions
149
Medicare Patients
6,519
Medicare Billing
$504,377
Payment Breakdown by Category
Food & Beverage$4,079 (79.4%)
Travel$968.86 (18.9%)
Education$89.20 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,079 | 143 | 79.4% |
| Travel and Lodging | $968.86 | 4 | 18.9% |
| Education | $89.20 | 2 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $1,856 | 16 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,284 | 39 | $0 (2024) |
| Impulse Dynamics (USA) Inc. | $217.60 | 6 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $205.49 | 11 | $0 (2024) |
| PFIZER INC. | $198.84 | 13 | $0 (2024) |
| Amgen Inc. | $156.33 | 9 | $0 (2024) |
| Novo Nordisk Inc | $144.78 | 9 | $0 (2024) |
| ABIOMED | $133.96 | 1 | $0 (2021) |
| Merck Sharp & Dohme LLC | $122.08 | 6 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $113.19 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $490.47 | 26 | AstraZeneca Pharmaceuticals LP ($154.05) |
| 2023 | $751.85 | 27 | Abbott Laboratories ($146.38) |
| 2022 | $2,309 | 44 | Abbott Laboratories ($1,710) |
| 2021 | $463.39 | 20 | ABIOMED ($133.96) |
| 2020 | $100.29 | 7 | AstraZeneca Pharmaceuticals LP ($44.46) |
| 2019 | $402.74 | 13 | AstraZeneca Pharmaceuticals LP ($297.76) |
| 2018 | $287.72 | 7 | AstraZeneca Pharmaceuticals LP ($287.72) |
| 2017 | $331.97 | 5 | AstraZeneca Pharmaceuticals LP ($264.47) |
All Payment Transactions
149 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: Cardiology | ||||||
| 12/11/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: Diabetes | ||||||
| 12/06/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/21/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: Obesity | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/14/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: Cardiovascular Diseases | ||||||
| 11/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/29/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/23/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Diabetes | ||||||
| 10/18/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $23.95 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/20/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/13/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/07/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: Diabetes | ||||||
| 09/03/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 08/26/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Cardiology | ||||||
| 08/16/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $30.71 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/14/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 08/06/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $16.47 | General |
| Category: Cardiovascular | ||||||
| 08/06/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: Diabetes | ||||||
| 08/01/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: NEUROLOGY | ||||||
| 07/25/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/26/2024 | Janssen Scientific Affairs, LLC | XARELTO (Drug) | Food and Beverage | In-kind items and services | $27.53 | General |
| Category: Cardiovascular & Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,497 | 1,765 | $322,998 | $89,537 |
| 2022 | 22 | 2,067 | 2,618 | $591,843 | $165,551 |
| 2021 | 20 | 1,629 | 2,086 | $516,923 | $156,711 |
| 2020 | 21 | 1,326 | 1,625 | $281,421 | $92,578 |
Total Patients
6,519
Total Services
8,094
Medicare Billing
$504,377
Procedure Codes
92
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 113 | 177 | $40,311 | $17,034 | 42.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 122 | 191 | $44,311 | $12,333 | 27.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 80 | 83 | $43,085 | $11,374 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 85 | 88 | $25,949 | $6,560 | 25.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 122 | 123 | $17,835 | $5,846 | 32.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 39 | 39 | $19,695 | $5,739 | 29.1% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 14 | 14 | $14,000 | $5,084 | 36.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 44 | 44 | $30,117 | $4,774 | 15.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 32 | 33 | $12,705 | $4,260 | 33.5% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 501 | 621 | $29,626 | $3,860 | 13.0% |
| 93355 | Ultrasound of heart with probe in esophagus during surgery on heart or great blood vessels with report | Facility | 2023 | 16 | 17 | $8,500 | $2,914 | 34.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 36 | 36 | $6,260 | $2,033 | 32.5% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 13 | 13 | $5,720 | $1,892 | 33.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $5,434 | $1,162 | 21.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 115 | 118 | $6,646 | $1,138 | 17.1% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 12 | 13 | $3,145 | $1,118 | 35.6% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 16 | 16 | $2,880 | $826.97 | 28.7% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 46 | 46 | $3,063 | $748.35 | 24.4% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 45 | 45 | $2,291 | $486.85 | 21.3% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 15 | 15 | $825.00 | $302.10 | 36.6% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 18 | 20 | $600.00 | $49.40 | 8.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 183 | 248 | $73,280 | $23,115 | 31.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 163 | 279 | $61,745 | $23,030 | 37.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 47 | 47 | $49,008 | $17,084 | 34.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 106 | 107 | $81,115 | $16,501 | 20.3% |
About Dr. James Kilcoyne, D.O
Dr. James Kilcoyne, D.O is a Cardiovascular Disease healthcare provider based in Langhorne, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2013. The National Provider Identifier (NPI) number assigned to this provider is 1104269190.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Kilcoyne, D.O has received a total of $5,137 in payments from pharmaceutical and medical device companies, with $490.47 received in 2024. These payments were reported across 149 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($4,079).
As a Medicare-enrolled provider, Kilcoyne has provided services to 6,519 Medicare beneficiaries, totaling 8,094 services with total Medicare billing of $504,377. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease, Internal Medicine
- Location Langhorne, PA
- Active Since 04/10/2013
- Last Updated 04/30/2024
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1104269190
Products in Payments
- MITRACLIP (Device) $1,856
- BRILINTA (Drug) $827.10
- ELIQUIS (Drug) $198.20
- FARXIGA (Drug) $184.21
- XARELTO (Drug) $140.72
- Impella (Device) $133.96
- ENTRESTO (Drug) $133.48
- Repatha (Biological) $124.25
- VERQUVO (Drug) $122.08
- OPTIMIZER (Device) $109.92
- Optimizer (Device) $107.68
- WAINUA (Drug) $105.94
- Ozempic (Drug) $100.90
- LifeVest (Device) $89.56
- Vascepa (Drug) $73.56
- LEQVIO (Drug) $72.01
- Cleerly Labs (Device) $55.00
- Assure WCD (Device) $53.99
- Roszet (Drug) $44.42
- VYNDAQEL (Drug) $42.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Langhorne
Rakesh Shah, M.d, M.D
Cardiovascular Disease — Payments: $136,380
Cardiovascular Disease $136,380
Frank Ammaturo, M.d, M.D
Cardiovascular Disease — Payments: $25,869
Cardiovascular Disease $25,869
Anand Haridas, M.d, M.D
Cardiovascular Disease — Payments: $18,256
Cardiovascular Disease $18,256
Andrew Friedman, Do, DO
Cardiovascular Disease — Payments: $9,374
Cardiovascular Disease $9,374
Eyad Kanawati, M.d, M.D
Cardiovascular Disease — Payments: $8,981
Cardiovascular Disease $8,981
Dr. Ranga Rao, Md, MD
Cardiovascular Disease — Payments: $8,305
Cardiovascular Disease $8,305